Are nucleos(t)ide analogues effective against severe outcomes in COVID-19 and hepatitis B virus coinfection?

Journal: Hepatology forum
Published Date: Sep 15, 2021

Abstract

BACKGROUND AND AIM: The impact of chronic hepatitis B virus (HBV) infection and nucleos(t)ide analogue (NUC) treatment on disease severity and clinical outcomes in patients with coronavirus 2019 (COVID-19) is unknown. The objective of this study was to determine whether HBV infection and the use of NUCs impacts mortality in patients with COVID-19.

Authors

  • Gupse Adali
    Department of Gastroenterology, University of Health Sciences Umraniye Training and Research Hospital, Istanbul, Turkey.
  • Pinar Gokcen
    Department of Gastroenterology, University of Health Sciences Umraniye Training and Research Hospital, Istanbul, Turkey.
  • Fatih Guzelbulut
    Department of Gastroenterology, University of Health Sciences Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey.
  • Ayca Gokcen Degirmenci Salturk
    Department of Gastroenterology, University of Health Sciences Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey.
  • Nihat Bugra Agaoglu
    GLAB (Genomic Laboratory), University of Health Sciences Umraniye Training and Research Hospital, Istanbul, Turkey.
  • Busra Unal
    Department of Gastroenterology, University of Health Sciences Umraniye Training and Research Hospital, Istanbul, Turkey.
  • Levent Doganay
    Department of Gastroenterology, University of Health Sciences Umraniye Training and Research Hospital, Istanbul, Turkey.
  • Kamil Ozdil
    Department of Gastroenterology, University of Health Sciences Umraniye Training and Research Hospital, Istanbul, Turkey.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals